Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo. (10th January 2023)

• Record Type: Journal Article
• Authors: Kong, Qian-Wen; Yang, Jiao; Li, Dan; Ding, Ya-Wei; Hu, Yu-Jie; Xue, Xiao-Chuan; Shi, Mei-Zhi; Jiang, Bo; Zhou, Yang-Yun; Zhang, Min; Hu, Jiu-Dong; Guo, Cheng; Chen, Jun-Jun; Han, Yong-Long
• Is Part Of: Journal of ethnopharmacology. Volume 300(2022)
• Publication Date: 2023-01-10
• Subjects: Tongguanteng injection -- Marsdenia tenacissima -- TAB1 -- Chemoresistance -- Ovarian cancer; TGT Tongguanteng injection -- PTX Paclitaxel -- OC Ovarian cancer -- CCK-8 Cell counting kit-8 -- A2780/T Ovarian cancer A2780 paclitaxel-resistant cells -- TAB1 Transforming growth factor-β-activated kinase 1 binding protein 1 -- TUNEL TdT-mediated dUTP Nick-End Labeling -- IHC Immunohistochemical -- CI Combination index -- IC50 Half maximal inhibitory concentration -- TAK1 Transforming growth factor-β-activated kinase 1 -- p38 MAPK Mitogen-activated protein kinase p38 -- Bax Bcl-2 associated X protein -- Bcl-2 B-cell lymphoma-2; Ethnopharmacology -- Periodicals; Pharmacognosy -- Periodicals; Herbs -- Periodicals; Herbs -- Periodicals; Pharmacognosy -- Periodicals; Pharmacognosie -- Périodiques; Herbes -- Périodiques; 615.1
• DOI: 10.1016/j.jep.2022.115728
• Languages: English
• ISSNs: 0378-8741

Abstract

Abstract: Ethnopharmacological relevance: Tongguanteng injection (TGT), the water extract from the stem of the Traditional Chinese hebal medicine of Marsdenia tenacissima (Roxb.) Wight et Arn. has been used as anticancer remedy for decades. TGT was not only used in the treatment of many malignant cancers extensively, but also an adjuvant anticancer drug with chemotherapeutics clinically. Aim of the study: To evaluate the effects of TGT on reversing paclitaxel (PTX) resistance and investigate the potential mechanism related to TAB1 in ovarian cancer (OC) in vitro and in vivo . Materials and methods: The synergistic effect and reversal ratio were determined by CCK8 assay and median-effect principle after the combination of TGT and PTX in OC A2780 and its PTX-resistant (A2780/T) cells. The biological functions in cell apoptosis, migration and invasion of A2780/T cells treated by PTX 4 μM with TGT 20, 40, 80 mg⋅mL -1 for 24 h were evaluated by colony formation, flow cytometry, wound healing and transwell assays. Proteomics technique and bioinformatic analysis were used to indentify the change of TAB1 expression in A2780/T cells induced by TGT. The association between TAB1 expression and human OC was analyzed by gene expression databases. In A2780/T cells, western blotting and colony formation assays were used to investigate the relationship between TAB1 expression and PTX resistance after TAB1 overexpression by TAB1 plasmids. The mechanism of TGT and PTX regulating TAB1 and its related proteins were explored by western blotting and flow cytometry assays after TAB1 knock-down using siTAB1. Moreover, TUNEL staining, immunohistochemistry (IHC) and histopathology were used to observe the antitumor effects, TAB1 and p-p38 expression and the tissues impairments in nude mice xenograft model established by A2780/T cells after the co-treatment with TGT and PTX by in vivo . Results: TGT combined with PTX showed the synergistic effect (CI<1), which could reverse the IC50 values of PTX in OC A2780 and A2780/T cells about 23.50 and 6.44 times, respectively. Besides, TGT combined with PTX could significantly inhibit the migration, invasion and promote apoptosis of A2780/T cells. We identified that TGT could induce TAB1 expression in A2780/T cells by proteomics analysis. TAB1 downregulation was significantly associated with tumorigenesis and poor prognosis in OC patients and PTX resistance in A2780/T cells. Furthermore, TGT could activate TAB1/TAK1/p38 MAPK signaling pathway targeting TAB1 and regulate the expression of Bax, Bcl-2 proteins to improve the sensitivity of A2780/T cells to PTX. TGT combined with PTX also showed a greater inhibition in tumor growth than PTX monotherapy in vivo . These promising results show the efficacy of TGT in reversing PTX resistance and provide a potential strategy that targeting TAB1/TAK1/p38 MAPK signaling pathway may improve the chemotherapy sensitivity in OC. Conclusions: Our results revealed that Tongguanteng injection could reverse paclitaxel resistance and the potential mechanism might be associated with the activation of TAB1/TAK1/p38 MAPK signaling pathway in OC in vitro and in vivo. TAB1 might be a pivotal target for reversing PTX resistance. This study will provide a theoretical basis for the combination of Tongguanteng injection and paclitaxel in clinic. Graphical abstract: Image 1 Highlights: Tongguanteng injection could reverse PTX resistance in ovarian cance r in vitro and in vivo. TAB1 may be a potential biomarker for PTX resistance in ovarian cancer. Tonguanteng injection activates TAB1/TAK1/p38 MAPK pathway to reverse PTX resistance in PTX-resistant ovarian cancer cells.